Company Overview and News

 
KLCI claws back to erase loss, Tenaga lifts

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI clawed back to erase its earlier losses at the midday break today, powered by gains at Tenaga Nasional Bhd and other select index-linked blue chips.
7084 7060 7036 0083 BATS 4162 7765 1163 5256 9334 5199 0154 KLKBY 5029 2445 5347 5258 3026 7216 TNABY 2836 TNABF HIPEF 1929

 
KLCI pares loss as select blue chips lend support

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): The FBM KLCI pared some of its loss at midday break today, against a backdrop of struggling regional markets.
HLFBF BRDBF 7036 1082 5681 6432 BATS 4162 7374 5256 5199 5210 1783 5029 3867 SGPBY 6888 AXXTF 5827 1902 HIPEF GEBHF 3719

 
KLCI remains in the red as select blue chips drag

2018-09-04 theedgemarkets
KUALA LUMPUR (Sept 4): The FBM KLCI remained in negative zone at mid-morning today, dragged by losses at select index-linked blue chips.
UPBMF 8621 6432 BATS 4162 2089 5014 8311 5199 7079 7617 KLKBY 5029 2445 4588 4456 3026 6888 MYPRY AXXTF HIPEF 3719

 
Stock With Momentum: Far East Holdings

2018-08-20 theedgemarkets
Far East Holdings Bhd (-ve) TRADING of shares in Far East Holdings Bhd (fundamental: 2.7/3; valuation: 0.5/3) triggered our momentum algorithm last Friday for the second time this year.
5029

 
KLCI struggles to recoup losses, stages marginal recovery

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): The FBM KLCI struggled to recoup some lost ground in the morning session today amid some choppy trading.
7047 BATS 4162 5246 5202 9334 6033 7233 2852 5029 PNADF 5347 5225 7668 6645 TNABY TNABF Q0F IHHHF PNAGF

 
KLCI pares gains as decliners overtake advancers

2018-08-10 theedgemarkets
KUALA LUMPUR (Aug 10): The FBM KLCI pared some of its gains at midday today as decliners overtook advancers, tracking the sentiment at most regional markets.
SPMXF UPBMF 7036 5681 BATS 4162 7765 5015 2089 5014 0131 6033 2593 2852 0143 5029 PNADF SPMXY 3883 0026 MYPRY PNAGF GEBHF

 
KLCI up 0.27%, select blue chips lift

2018-08-10 theedgemarkets
KUALA LUMPUR (Aug 10): The FBM KLCI rose 0.27% at mid-morning today, lifted by select blue chips, against the backdrop of weaker regional markets.
UPBMF 5681 BATS 4162 2089 5014 0131 2593 0143 5029 5225 0026 MYPRY Q0F IHHHF

 
KLCI seen opening flat, to hover above 1,790-level

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 10): The FBM KLCI is seen opening flat today in line with the weaker overnight close at Wall Street, but hover above the 1,790-level.
5843 5029 5216 SPMXY 7251 5225 SPMXF 5176 5272 Q0F IHHHF

 
Supermax, Gamuda, KPS, Sunway REIT, Bintai Kinden, Far East, Datasonic, Velesto, Barakah Offshore, MyEG, Ranhill, Asdion and IHH

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Supermax Corp Bhd, Gamuda Bhd, Kumpulan Perangsang Selangor Bhd (KPS), Sunway Real Estate Investment Trust, Bintai Kinden Corp Bhd, Far East Holdings Bhd, Datasonic Group Bhd, Velesto Energy Bhd, Barakah Offshore Petroleum Bhd, My EG Services Bhd, Ranhill Holdings Bhd, Asdion Bhd and IHH Healthcare Bhd.
7251 SPMXF 5176 5272 532843 5843 5029 5216 SPMXY 5225 FORTIS Q0F IHHHF

 
Far East 2Q net profit marginally up despite lower revenue

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): Far East Holdings Bhd has posted a 5% increase in net profit to RM10.52 million for the second quarter ended June 30, against RM10.04 million a year ago, notwithstanding lower revenue.
5029

 
KLCI up 0.26% in line with regional gains

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): The FBM KLCI rose 0.26% at the midday break today and stayed firmly above the 1,800-point level, tracking gains at regional markets.
HLFBF 7251 BATS 4162 2089 7077 5029 5347 1201 5225 TNABY 2836 IHHHF PNAGF 5183 PECGF UPBMF 1082 7765 6033 2593 PNADF TNABF Q0F 3719

 
KLCI holds position above 1,800 level, gains seen capped

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): The FBM KLCI managed to hold its position above the 1,800-point level at mid-morning today, but gains were seen capped in line with the subdued regional markets.
HLFBF 7172 5198 1082 7412 7043 7077 2852 5029 5347 5225 1201 3301 TNABY 5819 2836 TNABF Q0F IHHHF 3719

 
KLCI rises 0.39%, inches closer to 1,800 mark

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): The FBM KLCI rose 0.39% at the midday break today, as gains in select index-linked blue chips lifted it closer to the 1,800-point mark, tracking the advance at regional markets.
5198 7113 5032 6432 TPGVF BATS 4162 7765 0096 7043 5168 5014 TGLVY 5029 5225 3301 MYPRY Q0F IHHHF HRGHY

 
KLCI poised to test crucial 1,800-level, tracks regional gains

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): The FBM KLCI looked set to test the crucial 1,800-point level today as it rose in early trade, tracking gains at mosr regional markets.
5029 5347 3301 2542 TNABY MYPRY TNABF 5168 5014 HRGHY

 
KLCI pares gains, struggles to breach 1,800 level

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): The FBM KLCI pared some of its gains at mid-morning today, struggling to breach the 1,800-point level.
PBLOF BATS 4162 7087 7043 1295 5168 5014 5007 KLKBY 5029 2445 2542 5225 3867 5517 7668 2739 MYPRY 2836 Q0F IHHHF HRGHY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...